Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Nephritis, Hereditary

ClinicalTrials.gov lists 37 trials for Nephritis, Hereditary or a narrower condition beneath it. Genzyme, a Sanofi Company has the most among industry and government lead sponsors, with 3.

MeSH D009394 Urogenital Diseases C12 C16 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 10 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 3 Phase 4 Phase 4 2 Not applicable Not applicable 2 Observational Observational 16 Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 10 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 3 Phase 4 Phase 4 2 Not applicable Not applicable 2 Observational Observational 16

Trials per phase

37 of the 37 trials are tagged with Nephritis, Hereditary itself; the rest are tagged with a narrower condition beneath it.

Get the Nephritis, Hereditary report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Nephritis, Hereditary trials start? (15)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 5

1995: 1 trials (Observational 1) 2004: 1 trials (Phase 2 1) 2007: 2 trials (Observational 2) 2009: 1 trials (Observational 1) 2012: 4 trials (Observational 3, Phase 3 1) 2014: 1 trials (Observational 1) 2017: 3 trials (Observational 1, Phase 2/3 1, Phase 1 1) 2018: 2 trials (Observational 2) 2019: 2 trials (Phase 3 1, Phase 2 1) 2021: 4 trials (Observational 1, Phase 2 3) 2022: 5 trials (Observational 1, Not applicable 2, Phase 2 2) 2023: 4 trials (Observational 2, Phase 4 1, Phase 1/2 1) 2024: 3 trials (Phase 4 1, Phase 3 1, Phase 2 1) 2025: 2 trials (Phase 2/3 1, Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2
2025 2
2024 3
2023 4
2022 5
2021 4
2019 2
2018 2
2017 3
2014 1

Showing 10 of 15 earlier years.

Start your 14-day trial Email me all 15 earlier years as a PDF

No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Nephritis, Hereditary trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1
Phase 1/2 1
Phase 2 10
Phase 2/3 2
Phase 3 3
Phase 4 2
Not applicable 2
Observational 16

How many Nephritis, Hereditary trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 2
Recruiting 10
Active, not recruiting 4
Completed 16
Terminated 4

Showing 5 of 6 statuses.

Start your 14-day trial Email me all 6 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Nephritis, Hereditary trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Genzyme, a Sanofi Company 3
Biogen 2
Eloxx Pharmaceuticals, Inc. 2
Novartis Pharmaceuticals 2
Bayer 1

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Nephritis, Hereditary? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
BMS-512148 2
Bardoxolone Methyl 2
RAMIPRIL 2
Exaluren 2

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
ACE inhibitor 1
Benazepril, Valsartan and Fluvastatin 1
Benazepril hydrochloride 10 milligram (mg) Tab 1
RG012 1
SGLT2 Inhibitor 1

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Nephritis, Hereditary trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
End stage renal disease 10 2
Glomerular Filtration Rate Decreased 3 1
Acute kidney injury 2 2
Asthenia 2 2
Chronic kidney disease 2 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Nephritis, Hereditary? (25)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Treatment Approaches for Alport Syndrome. Journal of the American Society of Nephrology : JASN 2026 Yes
Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025 Yes
A Randomized Controlled Clinical Trial Testing Effects of Lademirsen on Kidney Function Decline in Adults with Alport Syndrome. Clinical journal of the American Society of Nephrology : CJASN 2024 Yes
PPAR δ Agonism Ameliorates Renal Fibrosis in an Alport Syndrome Mouse Model. Kidney360 2023 Yes
Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022 Yes

Showing 5 of 25 publications.

Start your 14-day trial Email me all 25 publications as a PDF

Prevalence (4)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Alport syndrome Point prevalence Unknown Europe Not stated Exact
Alport syndrome Point prevalence Unknown Europe Not stated Exact
Alport syndrome Prevalence at birth 1-9 / 100 000 Finland Not stated Exact
Alport syndrome Prevalence at birth 1-9 / 100 000 Finland Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Alport syndrome 63 Exact Orphanet Rare Disease Ontology (ORDO)
Alport syndrome 63 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages